Cargando…
DMAG, a novel countermeasure for the treatment of thrombocytopenia
BACKGROUND: Thrombocytopenia is one of the most common hematological disease that can be life-threatening caused by bleeding complications. However, the treatment options for thrombocytopenia remain limited. METHODS: In this study, giemsa staining, phalloidin staining, immunofluorescence and flow cy...
Autores principales: | Lin, Jing, Zeng, Jing, Liu, Sha, Shen, Xin, Jiang, Nan, Wu, Yue-Song, Li, Hong, Wang, Long, Wu, Jian-Ming |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8626956/ https://www.ncbi.nlm.nih.gov/pubmed/34837956 http://dx.doi.org/10.1186/s10020-021-00404-1 |
Ejemplares similares
-
Targeting a thrombopoietin-independent strategy in the discovery of a novel inducer of megakaryocytopoiesis, DMAG, for the treatment of thrombocytopenia
por: Wang, Long, et al.
Publicado: (2022) -
Ocimum flavone Orientin as a countermeasure for thrombocytopenia
por: Yadav, Marshleen, et al.
Publicado: (2018) -
Effects of 17-DMAG on diffuse large B-cell lymphoma cell apoptosis
por: Li, Jia-Jia, et al.
Publicado: (2017) -
17-DMAG dually inhibits Hsp90 and histone lysine demethylases in alveolar rhabdomyosarcoma
por: Singh, Shivendra, et al.
Publicado: (2020) -
17-DMAG regulates p21 expression to induce chondrogenesis in vitro and in vivo
por: Bertram, Karri L., et al.
Publicado: (2018)